import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "where-to-buy-efocipegtrutide-research-guide",
  title: "Where to Buy Efocipegtrutide (HM15211) for Research (2026 Guide)",
  description:
    "A researcher's sourcing guide for efocipegtrutide (HM15211), Hanmi Pharmaceutical's once-weekly GLP-1/GIP/glucagon triple receptor agonist. Covers quality standards, structural verification requirements for this long-chain acylated peptide, and what to look for in a verified supplier.",
  category: "Sourcing & Quality",
  readMinutes: 8,
  publishedAt: "2026-06-20",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Efocipegtrutide (HM15211) is Hanmi Pharmaceutical's once-weekly GLP-1/GIP/glucagon triple receptor agonist — a member of the emerging unimolecular triple agonist class that adds glucagon receptor (GCGR) activation to the GLP-1/GIP co-agonism pioneered by tirzepatide. By simultaneously engaging all three receptors, efocipegtrutide targets appetite suppression (GLP-1R), enhanced incretin potentiation (GIPR), and increased hepatic fat oxidation and thermogenesis (GCGR). Its clinical development program has focused on MASH (metabolic dysfunction-associated steatohepatitis) and obesity — disease models where the glucagon receptor's hepatic effects are mechanistically distinct from the pancreatic and central effects of GLP-1R/GIPR co-agonism.",
    },
    {
      type: "callout",
      text: "Efocipegtrutide is supplied for research purposes only. It is not approved by the FDA or any comparable regulatory authority for human therapeutic use. All sourcing and use references in this guide are for preclinical laboratory research contexts only.",
    },
    {
      type: "heading",
      text: "Why Researchers Study Efocipegtrutide",
    },
    {
      type: "paragraph",
      text: "The triple receptor agonist class is the current frontier in metabolic peptide pharmacology. Efocipegtrutide's research value stems from several properties that differentiate it within this class:",
    },
    {
      type: "list",
      items: [
        "Receptor targets: GLP-1R (agonist) + GIPR (agonist) + GCGR (agonist) — all three metabolic incretin/glucagon receptors",
        "Architecture: Long-acting acylated peptide; once-weekly subcutaneous dosing enabled by fatty acid modification extending half-life",
        "Hepatic specificity: GCGR activation adds direct hepatic fat oxidation — a liver-specific endpoint not addressable by GLP-1/GIP dual agonism alone",
        "MASH relevance: Clinical data in metabolic steatohepatitis shows hepatic histology improvements beyond what GLP-1 monotherapy achieves",
        "Comparator utility: Allows researchers to isolate the contribution of GCGR agonism by comparing efocipegtrutide vs. tirzepatide (GLP-1/GIP only) in matched animal models",
      ],
    },
    {
      type: "heading",
      text: "Structural Complexity and Sourcing Implications",
    },
    {
      type: "paragraph",
      text: "Efocipegtrutide's once-weekly activity is enabled by a fatty acid-based half-life extension strategy similar in concept to semaglutide's albumin-binding mechanism. This structural modification — a long-chain acyl group attached to the peptide backbone — substantially increases synthesis complexity compared to unmodified peptides. Researchers evaluating suppliers must account for this:",
    },
    {
      type: "list",
      items: [
        "Synthesis complexity: Acylated long-chain peptides require additional synthesis steps and have higher failure-mode rates than simple sequences",
        "Impurity profile complexity: Partially acylated species, truncated sequences, and acylation site errors are specific impurity types that RP-HPLC may not fully resolve — MS confirmation is essential",
        "Price floor: Legitimate research-grade acylated peptides of this length are expensive to manufacture; pricing significantly below market signals quality compromise",
        "Solubility considerations: The fatty acid modification affects solubility; reconstitution procedures differ from simple lyophilized peptides",
      ],
    },
    {
      type: "heading",
      text: "Minimum Quality Standards for Research-Grade Efocipegtrutide",
    },
    {
      type: "subheading",
      text: "HPLC Purity ≥98% with Full Chromatogram",
    },
    {
      type: "paragraph",
      text: "RP-HPLC documentation is the baseline requirement, but for an acylated peptide like efocipegtrutide, the chromatogram itself carries more information than the stated purity percentage. Researchers should examine the chromatogram for secondary peaks that indicate partially acylated species (which would show slightly different retention times) or truncated peptide fragments. A chromatogram showing a dominant single peak with minimal satellite peaks is a positive signal; a broad peak or clustered peaks suggest heterogeneous product.",
    },
    {
      type: "subheading",
      text: "Mass Spectrometry Identity Confirmation",
    },
    {
      type: "paragraph",
      text: "For efocipegtrutide's acylated structure, mass spectrometry is not optional — it is the only reliable method to confirm that the correct acylation has occurred at the correct position and that the full peptide sequence is intact. ESI-MS providing the expected molecular ion (accounting for the acyl modification) must appear on the COA. Suppliers unable to provide MS data for a structurally modified peptide of this complexity should not be used for controlled research.",
    },
    {
      type: "subheading",
      text: "Third-Party Laboratory Testing",
    },
    {
      type: "paragraph",
      text: "All HPLC and MS testing should be performed by a named, independently verifiable laboratory — not by the manufacturer's in-house team. The COA should identify the testing lab explicitly. For high-complexity acylated peptides, ISO/IEC 17025-accredited analytical laboratories represent the highest confidence level.",
    },
    {
      type: "subheading",
      text: "Endotoxin (LAL) Testing",
    },
    {
      type: "paragraph",
      text: "Any efocipegtrutide intended for in vivo rodent model work — particularly MASH or metabolic model studies involving parenteral administration — must be endotoxin-tested. LPS contamination at nanogram levels confounds hepatic inflammatory markers, metabolic cytokine profiles, and histological endpoints that are central to MASH research. LAL test results should appear on the COA with results in EU/mg and methodology stated.",
    },
    {
      type: "heading",
      text: "Supplier Evaluation Checklist",
    },
    {
      type: "table",
      headers: ["Quality Factor", "Minimum Standard", "Preferred Standard"],
      rows: [
        ["HPLC purity", "≥98% with chromatogram", "≥99% RP-HPLC with peak integration data"],
        ["Identity confirmation", "Molecular weight by ESI-MS", "ESI-MS confirming acylation site and intact sequence"],
        ["Testing origin", "Named third-party lab", "ISO/IEC 17025-accredited independent laboratory"],
        ["Endotoxin", "LAL result on COA", "<1 EU/mg with LAL methodology stated"],
        ["Acylation confirmation", "MS molecular weight match", "MS/MS fragmentation confirming acylation position"],
        ["Lot traceability", "Batch number on COA", "Lot-specific COA tied to individual vial labeling"],
        ["Storage and shipping", "Cold-chain disclosure", "Dry ice or gel-pack with temperature monitoring record"],
      ],
    },
    {
      type: "heading",
      text: "Red Flags When Evaluating Efocipegtrutide Sources",
    },
    {
      type: "list",
      items: [
        "No mass spectrometry data — acylation cannot be confirmed by HPLC alone",
        "Generic COA not tied to a specific lot or batch — template documents do not verify the actual product",
        "Testing lab unnamed or unverifiable — in-house testing by the seller has inherent conflict of interest",
        "No endotoxin data for a compound marketed for injection-route research applications",
        "Pricing at the same level as simple synthetic peptides — efocipegtrutide's acylated complexity demands higher synthesis cost",
        "No cold-chain shipping documentation — fatty acid-modified peptides degrade significantly faster at ambient temperature",
        "Single HPLC peak percentage without the actual chromatogram trace provided",
      ],
    },
    {
      type: "heading",
      text: "Triple Agonists vs. Dual Agonists: Choosing the Right Research Compound",
    },
    {
      type: "paragraph",
      text: "Researchers designing mechanistic studies across the incretin/glucagon pathway should understand the distinct receptor profiles of current co-agonist and triple agonist compounds.",
    },
    {
      type: "table",
      headers: ["Compound", "Receptor Targets", "Key Differentiator", "Primary Research Application"],
      rows: [
        ["Efocipegtrutide (HM15211)", "GLP-1R + GIPR + GCGR", "Glucagon receptor adds hepatic oxidation", "MASH, hepatic steatosis, triple agonism mechanistic studies"],
        ["Retatrutide", "GLP-1R + GIPR + GCGR", "Distinct peptide sequence, different GCGR/GIPR ratio", "Obesity, MASH, body composition in severe metabolic disease"],
        ["Tirzepatide", "GLP-1R + GIPR", "No glucagon receptor — baseline for triple vs. dual comparison", "Dual incretin agonism, insulin resistance, type 2 diabetes models"],
        ["Survodutide (BI 456906)", "GLP-1R + GCGR", "GIP-free glucagon co-agonism", "Hepatic-focused MASH and NAFLD models"],
        ["Semaglutide", "GLP-1R only", "Clean GLP-1R monotherapy reference", "GLP-1R endpoint baseline, cardiovascular research"],
      ],
    },
    {
      type: "paragraph",
      text: "Efocipegtrutide is specifically useful when the research question involves the glucagon receptor's contribution to hepatic outcomes in the presence of dual GLP-1/GIP background activity. Comparing efocipegtrutide directly against tirzepatide in matched metabolic models allows researchers to isolate the GCGR-specific signal. Comparing efocipegtrutide against survodutide allows isolation of the GIPR co-agonism contribution within a triple vs. dual framework.",
    },
    {
      type: "heading",
      text: "Storage and Reconstitution",
    },
    {
      type: "paragraph",
      text: "Efocipegtrutide should be stored lyophilized at −20°C with desiccant. The fatty acid modification reduces aqueous solubility compared to unmodified peptides — reconstitution should follow supplier-specific guidance, and working solutions should be prepared in small aliquots to minimize freeze-thaw cycles. For in vivo work, filter reconstituted solutions through a 0.22 µm membrane before use.",
    },
    {
      type: "heading",
      text: "Why Nexphoria for GLP-1 Pipeline Research Compounds",
    },
    {
      type: "paragraph",
      text: "Nexphoria provides research-grade compounds with HPLC and mass spectrometry documentation, batch-specific COA, and endotoxin testing as standard — accessible at purchase, not on request. For structurally complex acylated peptides like efocipegtrutide, analytical documentation is the primary differentiator between research-grade supply and commodity sourcing that cannot support rigorous experimental conclusions.",
    },
    {
      type: "disclaimer",
      text: "For research purposes only. Not for human use. Efocipegtrutide (HM15211) is an investigational compound under clinical evaluation by Hanmi Pharmaceutical. It is not approved by the FDA or any regulatory authority for therapeutic use in humans. All sourcing discussed in this guide is intended for licensed preclinical research applications only.",
    },
  ],
};
